Abstract
Disappointments and dropouts: Notable failures in pharma’s late-stage drug pipeline. AMG 899 Company: Amgen Indication: Cholesterol lowering Mechanism of action: CETP inhibitor Modality: Small molecule Phase: II Other: The compound was the centerpiece of Amgen's $300 million acquisition of Dezima Pharma in 2015. Anacetrapib Company: Merck & Co. Indication: Cholesterol lowering Mechanism of action: CETP inhibitor Modality: Small molecule Phase: III Other: A 30,000-patient study showed the drug was effective, but Merck concluded it wasn't sufficiently effective to be competitive in the cholesterol-lowering market. Intepirdine Company: Axovant Sciences Indication: Alzheimer's disease Mechanism of action: 5-HT6 receptor antagonist Modality: Small molecule Phase: III Other: The compound was licensed from GlaxoSmithKline and had already failed multiple studies. Mongersen Company: Celgene Indication: Crohn's disease Mechanism of action: Smad7 protein inhibitor Modality: Oligonucleotide Phase: III Other: Celgene ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
